3D-MRE and 2D-MRE for Assessing Cirrhosis and Portal Hypertension
Condition(s) studied
Investigational drug(s) / intervention(s)
3D-MRE: All imaging studies were performed by using a 3.0-T MRI system (Signa HDx, GE Healthcare) with an eight-channel phasedarray body coil.
HVPG: HVPG measurements are performed by well-trained interventional radiologists in accordance with standard operating procedures
2D-MRE: All imaging studies were performed by using a 3.0-T MRI system (Signa HDx, GE Healthcare) with an eight-channel phasedarray body coil.
HVPG: HVPG measurements are performed by well-trained interventional radiologists in accordance with standard operating procedures
Study summary
How to construct a novel, non-invasive, accurate, and convenient method to achieve prediction of hepatic venous pressure gradient (HVPG) is an important general problem in the management of portal hypertension in cirrhosis. We plan to compare the ability of three demensional-magnetic resonance elastography (3D-MRE) to two demensional-magnetic resonance elastography (2D-MRE) to establish a risk stratification system and perform tailored management for portal hypertension in cirrhosis.
Eligibility
Primary outcome measure(s)
- Accuracy of the features of 3D-MRE and 2D-MRE for assessing portal hypertension in cirrhosis. — 12 months
WIth HVPG as reference standand, the overall diagnostic perforemace (accuracy) for cirrhosis and portal hypertension of 3D-MRE and 2D-MRE was compared.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Shengjing Hospital of China Medical University | Shenyang | Liaoning | Recruiting |
More Shengjing Hospital trials in China
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06205992 on ClinicalTrials.gov ↗ ← All trials in China